Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I trial code: RD 787.36057 (MTX325-101)

Next Previous
Trial Profile

A Phase I trial code: RD 787.36057 (MTX325-101)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MTX 325 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man
  • Sponsors MISSION Therapeutics

Most Recent Events

  • 02 Jul 2024 According to a Mission Therapeutics media release, the company has been awarded $5.2 million from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and Parkinson's UK. The funding will support a 28-day dosing of MTX325 in patients with early-stage Parkinson's disease (PD), as part of Mission's ongoing MTX325 Phase I program.
  • 02 Jul 2024 According to a Mission Therapeutics media release, the single ascending part of trial in healthy volunteers has been completed. The multiple ascending dose stage of the study was initiated last month (June). Patient dosing is expected to start early in 2025.
  • 01 Mar 2024 Status changed from planning to recruiting, according to a Mission Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top